Skip to content
DataLookout
Menu

Ph3 Peds VitiNCT07896434

A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo

StatusNot Yet Recruiting
PhasePhase 3
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (>= 75% Improvement in F-VASI From Baseline)
Timeframe: At Week 48
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately Day 1150

Secondary (3)

Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (>= 50% Improvement in T-VASI From Baseline)
Percentage of Participants Achieving Facial-Vitiligo Area Scoring Index (F-VASI) 75 (>= 75% Improvement in F-VASI From Baseline)
Percentage of Participants with a Change in Baseline Cartoon Children's Dermatology Life Quality Index (CDLQI) score

Arms and interventions

Period A: Double-Blind Treatment PeriodExperimental

Pediatric participants will receive an adult-equivalent dose of upadacitinib or a matching placebo dose

Period B: Blinded Extension PeriodExperimental

Pediatric participants who complete Period A will continue into Period B and remain on blinded treatment. Pediatric participants initially randomized to blinded placebo (Period A) who have not achieved F-VASI 75 at Week 48 (nonresponders) will receive a blinded upadacitinib adult dose equivalent in Period B.

Drugs: Upadacitinib, Placebo for Upadacitinib